Stock Financial Ratios, Dividends, Split History

HEAR / Turtle Beach Corporation financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price21.06
Volume1,438,800.00
Market Cap ($M)29.63
Enterprise Value ($M)86.06
Book Value ($M)-20.42
Book Value / Share-1.49
Price / Book-0.81
NCAV ($M)-27.29
NCAV / Share-1.99
Price / NCAV-10.56
Share Statistics
Common Shares Outstanding 49,386,006
Weighted Average Number Of Shares Outstanding Basic 49,343,000
Weighted Average Number Of Diluted Shares Outstanding 49,343,000
Scoring Models
Piotroski F-Score0.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)n/a
Return on Assets (ROA)n/a
Return on Equity (ROE)n/a
Balance Sheet (mrq) ($M)
Assets52.31
Liabilities72.73
Quick Ratio1.41
Current Ratio2.16
Income Statement (mra) ($M)
Sales Revenue Net149,135,000.00
Operating Income4.80
Net Income-3.25
Earnings Per Share Basic-0.07
Earnings Per Share Diluted-0.07
Cash Flow Statement (mra) ($M)
Cash From Operations3.42
Cash from Investing-4.41
Cash from Financing-4.41
Identifiers and Descriptors
CUSIP900450107
Central Index Key (CIK)1493761

Split History

Stock splits are used by Turtle Beach Corporation to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

12h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

13h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

The Zacks Analyst Blog Highlights: Nike, Morgan Stanley, FedEx, TOTAL and ArcelorMittal

59m zacks
Chicago, IL –June 22, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Nike (NKE - Free Report) , Morgan Stanley (MS - Free Report) , FedEx (FDX - Free Report) , TOTAL S.A. (TOT - Free Report) and ArcelorMittal (MT - Free Report) . (30-0)

The Zacks Analyst Blog Highlights: Micron, NVIDIA, Texas Instruments, Diodes and Silicon Laboratories

59m zacks
Chicago, IL –June 22, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Micron Technology, Inc. (MU - Free Report) , NVIDIA Corp. (NVDA - Free Report) , Texas Instruments Inc. (TXN - Free Report) , Diodes Inc. (196-0)

Zacks Industry Outlook Highlights: ANSYS, Citrix, Cadence and Adobe

1h zacks
Chicago, IL – June 22, 2018 – Today, Zacks Equity Research discusses Computer Software, including ANSYS, Inc. (ANSS - Free Report) , Citrix Systems, Inc. (CTXS - Free Report) , Cadence Design Systems, Inc. (CDNS - Free Report) and Adobe Systems, Inc. (ADBE - Free Report) (98-0)

The Zacks Analyst Blog Highlights: Cronos Group

23h zacks
Chicago, IL –June 21, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Cronos Group (CRON - Free Report) . (45-0)

Russell 2000 Hits Record High: 5 Top-Ranked Small-Cap Picks

2018-06-21 zacks
Small-cap stocks have emerged as diamonds in the rough pushing aside the large-cap stocks in 2018. The small-cap centric Russell 2000 (RUTX) index is breaking new grounds while the broader market continues languish in face of severe fluctuations. Investors’ apprehensions regarding an impending global trade war has taken its toll on the market. However, Russell 2000 continues to achieve one milestone after the other. (5-0)

CUSIP: 900450107